EyePoint's third-quarter numbers matter far less than what happened around them. The company reported a loss of $1.07 per share, missing the -$0.88 consensus by 21.6%, and earnings fell 25.9% from a year earlier as the loss widened from $0.85 per share. Revenue of $0.76 million beat the $0.2 million consensus by 278.0% but fell 21.7% year over year, and at this scale it is irrelevant. The central development is that the core investment thesis broke. Both Phase 3 wet AMD trials, LUGANO and LUCIA, missed their primary non-inferiority endpoint, and the wet AMD program is being shut down. EyePoint is now a single-asset diabetic macular edema (DME) story, and its guided cash runway ends just before that data arrives.

The income statement shows a company spending at peak Phase 3 intensity just as its lead indication failed. Net loss rose to $95.6 million from $59.7 million, driven by R&D of $81.7 million versus $47.8 million a year earlier. The per-share loss widened less than the dollar loss only because the weighted share count rose to 89.2 million from 70.2 million, which is dilution rather than improvement. The balance sheet is the bigger story. Cash and investments fell to $118 million from $223 million at the end of the first quarter and $306 million at year-end 2025. The release also lists going-concern uncertainty and Nasdaq minimum-bid compliance among its risks, a notable shift in language for a company that months ago talked about blockbuster potential.

The call made the reset explicit. Management's tone moved from "strong conviction" to "deeply disappointed" and capital preservation. Several things were cut or dropped:

• The wet AMD NDA and the commercial build-out are gone.
• The workforce is being reduced by about 53%, for roughly $30 million in annualized savings.
• The market-opportunity framing shrank from roughly $15 billion in the U.S. across wet AMD and DME to a $5 billion global DME market.
• Runway guidance, previously into the fourth quarter of 2027 on every recent call, now reaches only the late third quarter of 2027. That includes the $10 million already raised through the at-the-market facility.

DME topline data for COMO and CAPRI is expected early in the fourth quarter of 2027. The CFO conceded the company "just about" reaches that readout, so further financing or business development looks likely before shareholders see the data that now defines the company.

Management's case for DME is not empty. COMO and CAPRI completed enrollment of more than 550 patients in five months. The Phase 2 VERONA trial showed a 7.1-letter visual gain and a 76-micron CST reduction at Week 24, with 73% of DURAVYU patients supplement-free versus 50% on aflibercept. In wet AMD, DURAVYU delivered superior treatment-burden reductions of 42% and 38%, and the safety profile was clean with repeat dosing. A pooled analysis of supplement-free patients showed nominal BCVA non-inferiority. Management also argues that DURAVYU's activity against both VEGF and IL-6 inflammatory pathways fits DME biology better.

Bears, however, have legitimate ammunition. The wet AMD data showed biological activity on secondary measures that did not translate into the visual-acuity endpoint regulators require. The DME trials use the same non-inferiority-versus-aflibercept design. Analysts also flagged three features that add risk:

• The DME control arm receives two additional aflibercept loading doses, which could make non-inferiority harder to show.
• No futility analysis is planned.
• A protocol amendment loosened the supplement trigger to a more-than-5-letter loss plus at least a 50-micron CST increase, from a 10-letter loss, specifically to protect the non-inferiority margin.

That amendment is a sensible adjustment, but it also shows management is aware of the same vulnerability that sank wet AMD.

The market has already delivered its verdict. Shares have collapsed 97.0% since opening at $11.88 after the August report. They hit an inter-earnings high of $14.76 on August 14, three days before the LUGANO miss, and set a 52-week low of $0.33 on November 6. At $0.36, the stock sits about 96.6% below its $10.40 200-day moving average, and price and AVWAP trend readings remain negative. Investor sentiment swung sharply, from -0.47 to +0.56. That swing likely reflects speculative interest at distressed levels more than renewed fundamental confidence. Management itself argued the current valuation assigns little value to DME.

The bottom line is that the earnings miss is a footnote to a far larger event. EyePoint lost its lead indication, half its workforce, and most of its cash cushion in one quarter. What remains is a binary DME bet with credible Phase 2 support but structural trial risks, and a runway that does not quite reach the readout without more capital. Speculative interest may be returning, but the setup now hinges on financing terms and on whether COMO and CAPRI can succeed where LUGANO and LUCIA did not.